氧化苦参碱对大鼠溃疡性结肠炎模型结肠组织中Toll样受体9、核因子-κB mRNA表达的影响

摘要

目的：：探讨氧化苦参碱对溃疡性结肠炎大鼠模型结肠组织中Toll样受体9(TLR9)、核因子-κB(NF-κB)mRNA表达的影响。方法：SPF级SD大鼠75只，随机分为模型组、氧化苦参碱组、美沙拉嗪组、氧化苦参碱+美沙拉嗪组和空白对照组各15只。实验1周后每组各取3只大鼠结肠组织进行大体形态学及组织学观察，第16天剩余的大鼠处死取结肠组织，应用逆转录多聚酶链反应方法检测各组TLR9、NF-κB mRNA的表达水平。结果：模型组结肠组织中TLR9表达水平均明显高于其他各组(P<0.01)，氧化苦参碱+美沙拉嗪组中NF-κB mRNA表达水平均低于模型组、氧化苦参碱组和美沙拉嗪组(P<0.05~P<0.01)，氧化苦参碱组和美沙拉嗪组2项指标表达水平差异均无统计学意义(P>0.05)。结论：氧化苦参碱可干预TLR9、NF-κB mRNA在炎症性结肠组织中的表达，进而抑制溃疡性结肠炎炎症反应；氧化苦参碱联合美沙拉嗪比单用氧化苦参碱或美沙拉嗪抑制作用更强。%Objective:To investigate the regulative mechanism of oxymatrine on the expression of toll-like receptor 9 ( TLR9 ) and nuclear factor-κB(NF-κB) at mRNA level in colonic tissue of rats with ulcerative colitis(UC). Methods:Seventy-five adult SD rats with SPF grade were divided into 5 groups randomly:control group,oxymatrine treatment group,mesalazine treatment group,oxymatrine and mesalazine combined treatment group, and model group. One week after the experiment, three rats in each group were randomly selected and executed for observing the histological changes of colonic tissue. On the 15th day the remaining rats were executed to detect the expressions of TLR9 and NF-κB at mRNA level in colonic tissue by reverse transcription polymerase chain reaction. Results:The mRNA expression level of TLR9 in UC model rat colonic tissue were higher than that in drug treatment groups and control group( P<0. 01). In the treated groups,the lower expression of NF-κB at mRNA level was shown in oxymatrine+mesalazine combined group than that in model group,oxymatrine group and mesalazine group alone,which had the statistical differences(P<0. 05 to P<0. 01),but there had no difference between the oxymatrine group and mesalazine group(P>0. 05). Conclusions:Oxymatrine could regulate TLR9 and NF-κB expressions at mRNA level in inflammatory colonic tissue,thereby inhibited the inflammatory response of UC. The combined treatment of oxymatrine and mesalazine had a better effect on blocking the TLR9 and NF-κB pathway to alleviate the inflammatory reaction in UC than oxymatrine or mesalazine treatment alone.